Femasys stock.

Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.Institutional Ownership and Shareholders. Femasys Inc (US:FEMY) has 32 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,650,299 shares. Largest shareholders include Clear Street Llc, Clear Creek Financial Management, LLC, Bank Of America ...Get Femasys Inc (FEMY.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

- FemaSeed ® is the first-ever, first-line approach designed to deliver sperm directly where conception occurs -. ATLANTA, April 18, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the ...Complete Femasys Inc. stock information by Barron's. View real-time FEMY stock price and news, along with industry-best analysis.

The latest price target for Femasys (NASDAQ: FEMY) was reported by HC Wainwright & Co. on Tuesday, November 14, 2023. The analyst firm set a price target for ...Femasys story: Human Papillomavirus Testing Pap Test Market By Test Type,Application,Business Growth and Is Grow at a EIN News and other headlines for Femasys Stock

FEMY Femasys Bull Pennant On 7/13/2021 Jonestrading brokerage Initiated Coverage with a Buy rating and a $8.45 Price Target On 7/13/2021 Chardan Capital brokerage Initiated Coverage with a Buy rating and a $25.00 Price Target How do you explain such a big difference in valuation? Get the latest Femasys Inc. (FEMY) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Femasys Inc. Common Stock (FEMY) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Live Key Data Bid Price and Ask Price The bid & ask refers to the price that an... At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...

Femasys expects the resulting patent, when issued, will have an anticipated expiration in 2039, at the earliest. In October, Femasys regained compliance with Nasdaq’s minimum bid price requirement, after having received a notice on June 1, 2023 from Nasdaq that they were not in compliance with such requirement.

The Femasys Inc. stock price fell by -3.27% on the last day (Wednesday, 29th Nov 2023) from $1.01 to $0.98.During the last trading day the stock fluctuated 6.91% from a day low at $0.96 to a day high of $1.03.The price has fallen in 5 of the last 10 days but is still up by 5.05% over the past 2 weeks. Volume fell on the last day along with the …John Dyett has not been actively trading shares of Femasys over the course of the past ninety days. Most recently, on Wednesday, June 23rd, John Dyett bought 53,500 shares of Femasys stock. The stock was acquired at an average cost of $12.93 per share, with a total value of $691,755.00. Learn More on John Dyett's trading history.Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.The stock of Femasys Inc (FEMY) has seen a -20.00% decrease in the past week, with a -27.78% drop in the past month, and a 152.43% flourish in the past quarter. The volatility ratio for the week is 12.52%, and the volatility levels for the past 30 days are at 13.78% for FEMY. The simple […]0.13% QQQ 389.08 0.11% SPIKE – 3.39% BTC/USD 37034.02 0.9542% DIA 353.48 0.09% 187.02 0.81% TLT 91.10 1.45% Femasys Inc (NASDAQ:FEMY) $1.04 …Web

Payment. $1,459.35/mo. -. -. calculate payment. There’s a saying on Wall Street that traders often sell the news. Well, that hasn’t been the case with a tiny reproductive health company ...SEC Filings. Select Year: Filter filing type: Date Filing Type Filing Description Download / View. 11/30/2023. S-3. Securities Registration Statement (simplified form) 11/29/2023. 8-K. Current report filing.Femasys Inc. Common Stock (FEMY) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Live Key Data Bid Price and Ask Price The bid & ask refers to the price that an... SEC Filings. Select Year: Filter filing type: Date Filing Type Filing Description Download / View. 11/30/2023. S-3. Securities Registration Statement (simplified form) 11/29/2023. 8-K. Current report filing.- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to deliver sperm directly to where conception …A few examples include why shares of Tharimmune (NASDAQ: THAR) and Femasys (NASDAQ: FEMY) stock are up, as well as the biggest pre-market stock movers for today. All of that info is available at ...Femasys Inc (NASDAQ: FEMY) shares surged after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a 

ATLANTA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ...

What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has ...15 nov 2023 ... ... shares of common stock at $1.18 per share, expiring one year from issuance, and warrants to purchase approximately 5.8 million shares of ...Femasys' cash burn of US$10.0m is about 50% of its US$20m market capitalisation. ... and we've picked out 3 warning signs for Femasys that investors should know when investing in the stock. ...Femasys story: Femasys Inc Shares Close the Day 14.4 percent Lower - Daily Wrap - Nasdaq and other headlines for Femasys StockDec 1, 2023 · The Femasys Inc. stock price fell by -3.27% on the last day (Wednesday, 29th Nov 2023) from $1.01 to $0.98. During the last trading day the stock fluctuated 6.91% from a day low at $0.96 to a day high of $1.03. The price has fallen in 5 of the last 10 days but is still up by 5.05% over the past 2 weeks. Femasys : FEMY got FDA ... This revolutionary clearance has primed ICU for an explosion, and accordingly, analysts label the stock as a Buy with an average target price of $1.00. That represents a ...In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock.These promising developments of Femasys’s products further solidify the Buy rating. In another report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price ...Employees: 30. 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE, GA 30024. 770-500-3910. femasys.com. Femasys Inc. focuses on women's healthcare market in the United States. The company develops permanent birth …

Apr 19, 2023 · In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions.

That’s a massive surge in trading volume compared to Femasys’ daily average of about 3.3 million shares. FEMY stock is up 180.9% as of Tuesday morning after closing out Monday down 63.2% year ...

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. FEMY, a biomedical company focused on meeting significant unmet needs for women worldwide with a broad …WebOur Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in …Description. Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient ... Sep 27, 2023 · Femasys has a market capitalisation of US$22m and burnt through US$11m last year, which is 50% of the company's market value. ... It does not constitute a recommendation to buy or sell any stock ... Sep 27, 2023 · Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including FemaSeed ® an FDA- cleared infertility treatment, FemBloc ® a lead late-clinical stage product candidate for permanent birth control, and FDA-cleared, innovative diagnostic products. Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including FemaSeed ® an FDA- cleared infertility treatment, FemBloc ® a lead late-clinical stage product candidate for permanent birth control, and FDA-cleared, innovative diagnostic products.Currently, the analyst consensus on Femasys is a Strong Buy with an average price target of $6.67. See today’s best-performing stocks on TipRanks >> Trevena (TRVN)Jul 27, 2023 · FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth controlATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ ... Stock Info Stock Quote Price $1.03 Volume 3,368,658 Change +0.12 % Change +12.72% Today's Open $0.96 Previous Close $0.91 Intraday High $1.14 Intraday …Web

AIM ImmunoTech Inc. 0.47. -0.002. -0.4237%. Get Femasys Inc (FEMY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Femasys : Corporate Presentation June 2023. Disrupting Convention in Women's Health Through Continuous Innovation. This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current ...May 26, 2023 · At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock.Instagram:https://instagram. zip recruiter stockagnc dividend datesgehc quotebest share to buy today Nov. 30, 2023 5:40 PM ET Femasys Inc. (FEMY) By: Tiyashi Datta, SA News Editor. Femasys ( NASDAQ: FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an ...Femasys Inc (NASDAQ:FEMY) trade information. Femasys Inc (FEMY) registered a -2.33% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.33% in intraday trading to $0.93 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -9.71%, and it has moved … best broker for forexnitro wood ingredients Femasys (NASDAQ:FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an aggregate of 18.11M shares of common stock …Web nasdaq mcft Since then, however, the stock has slipped by 47%. Writing on Femasys for Chardan Research, 5-star analyst Keay Nakae takes care to laud “the potential of its next generation products addressing ...ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a suite of product candidates and products that include minimally invasive, in-office technologies for reproductive health, announced that the United States Patent and …The stock is up ~205% in after-hours trading on Monday. Femasys (FEMY) says that FeedSeed is "less invasive and more affordable than assisted reproduction procedures, such as in vitro ...